198 related articles for article (PubMed ID: 21785281)
1. Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants.
van der Ley P; van den Dobbelsteen G
Hum Vaccin; 2011 Aug; 7(8):886-90. PubMed ID: 21785281
[TBL] [Abstract][Full Text] [Related]
2. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.
van de Waterbeemd B; Streefland M; van der Ley P; Zomer B; van Dijken H; Martens D; Wijffels R; van der Pol L
Vaccine; 2010 Jul; 28(30):4810-6. PubMed ID: 20483197
[TBL] [Abstract][Full Text] [Related]
3. A critical contribution of both CD28 and ICOS in the adjuvant activity of Neisseria meningitidis H44/76 LPS and lpxL1 LPS.
van Berkel ME; Schrijver EH; van Mourik A; Tesselaar K; van der Ley P; Steeghs L; Oosterwegel MA
Vaccine; 2007 Jun; 25(24):4681-8. PubMed ID: 17499399
[TBL] [Abstract][Full Text] [Related]
4. Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives.
Arigita C; Luijkx T; Jiskoot W; Poelen M; Hennink WE; Crommelin DJ; Ley Pv; Els Cv; Kersten GF
Vaccine; 2005 Oct; 23(43):5091-8. PubMed ID: 15993990
[TBL] [Abstract][Full Text] [Related]
5. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
Sanders H; Feavers IM
Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
[TBL] [Abstract][Full Text] [Related]
7. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
[TBL] [Abstract][Full Text] [Related]
8. Induction of immune responses by purified outer membrane protein complexes from Neisseria meningitidis.
Marzoa J; Sánchez S; Costoya L; Diéguez-Casal E; Freixeiro P; Brookes C; Allen L; Taylor S; Gorringe AR; Ferreirós CM; Criado MT
Vaccine; 2012 Mar; 30(13):2387-95. PubMed ID: 21911024
[TBL] [Abstract][Full Text] [Related]
9. Short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis of potential value for production of outer membrane vesicle vaccines.
Andersen SR; Bjune G; Lyngby J; Bryn K; Jantzen E
Microb Pathog; 1995 Sep; 19(3):159-68. PubMed ID: 8559044
[TBL] [Abstract][Full Text] [Related]
10. Meningococcal Outer Membrane Vesicle Composition-Dependent Activation of the Innate Immune Response.
Zariri A; Beskers J; van de Waterbeemd B; Hamstra HJ; Bindels TH; van Riet E; van Putten JP; van der Ley P
Infect Immun; 2016 Oct; 84(10):3024-33. PubMed ID: 27481244
[TBL] [Abstract][Full Text] [Related]
11. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
[TBL] [Abstract][Full Text] [Related]
12. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity.
van der Ley P; Steeghs L; Hamstra HJ; ten Hove J; Zomer B; van Alphen L
Infect Immun; 2001 Oct; 69(10):5981-90. PubMed ID: 11553534
[TBL] [Abstract][Full Text] [Related]
13. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin.
Koeberling O; Seubert A; Granoff DM
J Infect Dis; 2008 Jul; 198(2):262-70. PubMed ID: 18505380
[TBL] [Abstract][Full Text] [Related]
14. Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage.
Delbos V; Lemée L; Bénichou J; Berthelot G; Deghmane AE; Leroy JP; Houivet E; Hong E; Taha MK; Caron F;
Vaccine; 2013 Sep; 31(40):4416-20. PubMed ID: 23856330
[TBL] [Abstract][Full Text] [Related]
15. Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity.
Arenas J; van Dijken H; Kuipers B; Hamstra HJ; Tommassen J; van der Ley P
Clin Vaccine Immunol; 2010 Apr; 17(4):487-95. PubMed ID: 20107001
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.
Keiser PB; Biggs-Cicatelli S; Moran EE; Schmiel DH; Pinto VB; Burden RE; Miller LB; Moon JE; Bowden RA; Cummings JF; Zollinger WD
Vaccine; 2011 Feb; 29(7):1413-20. PubMed ID: 21199704
[TBL] [Abstract][Full Text] [Related]
17. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
[TBL] [Abstract][Full Text] [Related]
18. Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination.
Fisseha M; Chen P; Brandt B; Kijek T; Moran E; Zollinger W
Infect Immun; 2005 Jul; 73(7):4070-80. PubMed ID: 15972495
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant effects elicited by novel oligosaccharide variants of detoxified meningococcal lipopolysaccharides on Neisseria meningitidis recombinant PorA protein: a comparison in mice.
Mehta OH; Norheim G; Hoe JC; Rollier CS; Nagaputra JC; Makepeace K; Saleem M; Chan H; Ferguson DJ; Jones C; Sadarangani M; Hood DW; Feavers I; Derrick JP; Pollard AJ; Moxon ER
PLoS One; 2014; 9(12):e115713. PubMed ID: 25545241
[TBL] [Abstract][Full Text] [Related]
20. Plasma fibrinogen levels after vaccination with a native outer membrane vesicle vaccine for Neisseria meningitidis.
Keiser PB; Miller LB; Biggs-Cicatelli S; Zollinger WD
Vaccine; 2009 Nov; 27(49):6809-13. PubMed ID: 19761833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
